Evidence map›Paper›PMID 33484299›Full record

ArticlePsychopharmacology2021

MDPV "high-responder" rats also self-administer more oxycodone than their "low-responder" counterparts under a fixed ratio schedule of reinforcement.

Brenda M Gannon, Kenner C Rice, Kevin S Murnane

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. The Use of Oxytocin for the Treatment of Opioid Use Disorder.Current pain and headache reports · 2023
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Brenda M GannonDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Atlanta, GA, 30341, USA.
Kenner C RiceMolecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, 20852, USA.
Kevin S MurnaneDepartment of Pharmaceutical Sciences, Mercer University College of Pharmacy, Atlanta, GA, 30341, USA. kmurna@lsuhsc.edu.ORCID http://orcid.org/0000-0002-8143-0541
Louisiana State University in Shreveport · USMercer University Health Sciences Center · USNational Institute on Drug Abuse · US

Funding

Receptor pharmacology and toxicology of second-generation pyrrolidine "bath salt" cathinonesR21DA040907 · NIDA · NORTHEASTERN UNIVERSITY · PI CANAL, CLINTON E, MURNANE, KEVIN SEAN · 2016 to 2017
$493k
A nanotechnology approach to higher brain penetrance and sustained brain delivery of intranasal oxytocinR41DA046215 · NIDA · DD THERAPEUTICS, LLC · PI MURNANE, KEVIN SEAN · 2018 to 2018
$150k
Georgia Research Alliance GRA.VL19.I1/2NIDA NIH HHS DA040907NIDA NIH HHS DA046215NIDA NIH HHS R21 DA040907NIDA NIH HHS R41 DA046215
6 · The paper itself

Abstract

rationaleOxycodone is one of the most commonly prescribed and most frequently abused opioid analgesics, yet little is known regarding individual vulnerabilities to oxycodone abuse. The synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) has been shown to produce a "high-responder" phenotype characterized by increased drug intake and responding during periods of signaled drug unavailability (e.g., during post-infusion timeouts) in ~ 40% of male Sprague-Dawley rats. This phenotype also transfers to other psychostimulants (e.g., cocaine and methamphetamine), but it is unknown whether this phenotype transfers to other (non-stimulant) drugs of abuse.

objectivesThe present study aimed to (1) reestablish the "high-responder" phenotype in male Sprague-Dawley rats (n = 11) that acquired self-administration of MDPV (0.032 mg/kg/inf) on a fixed ratio 1 (FR1) schedule of reinforcement and (2) compare full dose-response curves for MDPV and oxycodone self-administration under an FR5 schedule of reinforcement.

resultsMDPV was ~ 3-fold more potent at maintaining peak levels of behavior and resulted in greater overall drug intake than oxycodone. High levels of timeout responding were noted in a subset of rats that acquired MDPV self-administration ("high-responders", n = 5), and the FR5 dose-response curve for MDPV was shifted upward for these rats relative to their "low-responder" (n = 6) counterparts. "High-responders" also self-administered more infusions of oxycodone under an FR5 schedule of reinforcement than "low-responders"; however, this was not coupled with increased levels of timeout responding.

conclusionsThe present data suggest that a subset of individuals with a history of using synthetic cathinones may be particularly vulnerable to the abuse of oxycodone.

Indexed as

Self AdministrationAnimalsBenzodioxolesCentral Nervous System StimulantsConditioning, OperantDose-Response Relationship, DrugMaleNarcoticsOxycodonePyrrolidinesRatsRats, Sprague-DawleyReinforcement ScheduleSynthetic CathinoneBenzodioxolesCentral Nervous System StimulantsNarcoticsOxycodonePyrrolidinesSynthetic CathinoneAddiction-like phenotypeBath saltsCathinonesMDPVOpioidsOxycodoneRatsSelf-administration

Identifiers

PMID33484299
OpenAlexW3122784532

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.